financetom
DARE
financetom
/
Healthcare
/
DARE
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Daré Bioscience, Inc.DARE
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States.

It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy.

The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth.

Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal healt

Latest News >
Thomson Reuters Q3 Adjusted Earnings, Revenue Beat Forecasts
Thomson Reuters Q3 Adjusted Earnings, Revenue Beat Forecasts
Nov 4, 2025
07:18 AM EST, 11/04/2025 (MT Newswires) -- Thomson Reuters ( TMSOF ) up 3.6% in U.S. pre-market trading, said Tuesday that third-quarter adjusted earnings and revenue both rose, beating estimates. Adjusted earnings, which excludes most one-time items, was US$383 million, or $0.85 per share, compared with $359 million, or $0.80 per share, in the prior year period. The result beat...
UL Solutions Q3 revenue beats; announces restructuring initiative
UL Solutions Q3 revenue beats; announces restructuring initiative
Nov 4, 2025
Overview * UL Solutions ( ULS ) Q3 revenue grows 7.1% to $783 mln, beating analyst expectations * Adjusted EBITDA of $217 mln beats estimates, reflecting strong operational performance * Company announces restructuring initiative to reduce expenses and improve efficiency Outlook * UL Solutions ( ULS ) expects 2025 organic revenue growth of 5.5% to 6% * Company anticipates 2025...
CPI Card posts higher Q3 sales, profit
CPI Card posts higher Q3 sales, profit
Nov 4, 2025
Overview * CPI Card Q3 2025 sales up 11% to $138 mln, driven by Arroweye and instant issuance * Net income increased 78% to $2.3 mln, but missed analyst expectations * Adjusted EBITDA decreased 7% to $23.4 mln due to lower gross margins and tariffs Outlook * CPI forecasts 2025 net sales growth in low double-digit to low teens range...
Urban One Q3 revenue falls 16% to $92.7 mln
Urban One Q3 revenue falls 16% to $92.7 mln
Nov 4, 2025
Overview * Urban One ( UONE ) Q3 revenue declines 16% yr/yr to $92.7 mln * Company reports Q3 net loss of $2.8 mln, improved from $31.8 mln loss last year * Adjusted EBITDA for Q3 falls to $14.2 mln from $25.4 mln in 2024 Outlook * Urban One ( UONE ) reduces full-year Adjusted EBITDA guidance to $56-58 mln...
Copyright 2023-2026 - www.financetom.com All Rights Reserved